Literature DB >> 2465159

Positive inotropic effects in isolated ventricular myocardium from non-failing and terminally failing human hearts.

M Näbauer1, M Böhm, L Brown, F Diet, M Eichhorn, B Kemkes, B Pieske, E Erdmann.   

Abstract

The positive inotropic responses to isoprenaline, dobutamine, histamine, forskolin, isobutyl-methylxanthine (IBMX), dibutyryl-cyclic adenosine monophosphate (db-cAMP), ouabain and calcium were studied in isolated, electrically driven papillary muscle strips from either terminally failing human hearts or non-failing donor myocardium. The positive inotropic effect of calcium has been taken to evaluate the maximal force of contraction of each individual muscle strip ('contractile reserve'). In the non-failing heart, the maximal positive inotropic effect of isoprenaline, dobutamine, IBMX, ouabain and calcium were not significantly different, but were significantly greater than histamine. In terminally failing hearts, the positive inotropic effects of agents stimulating the adenylate cyclase by a receptor-dependent mechanism (isoprenaline, dobutamine and histamine) and the phosphodiesterase inhibitor IBMX are less than in the normal heart. Furthermore, these compounds gave a markedly reduced inotropic effect compared with forskolin, db-cAMP and ouabain, which gave maximal responses similar to calcium in the failing hearts. The data did not differ when the increase of force of contraction was related to the diameter of each preparation. These results indicate that a defect in adenylate cyclase occurs in the failing human heart, presumably located at the regulatory stimulatory subunit (Gs) of the adenylate cyclase since effects through stimulatory receptors were reduced. Responses from activation of the catalytic subunit or through cAMP-dependent protein kinases were less affected. Since the positive inotropic effect of IBMX is also impaired, it is suggested that the basal rate of cAMP production is also reduced in heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2465159     DOI: 10.1111/j.1365-2362.1988.tb01274.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice.

Authors:  Sebastian Uhl; Marc Freichel; Ilka Mathar
Journal:  J Vis Exp       Date:  2015-09-17       Impact factor: 1.355

2.  RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload.

Authors:  J H Rogers; P Tamirisa; A Kovacs; C Weinheimer; M Courtois; K J Blumer; D P Kelly; A J Muslin
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  Incomplete reversal of beta-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors.

Authors:  D G Wynne; P A Poole-Wilson; S E Harding
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

4.  Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium.

Authors:  H R Zerkowski; A Broede; K Kunde; S Hillemann; E Schäfer; M Vogelsang; M C Michel; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-04       Impact factor: 3.000

5.  Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure.

Authors:  C L Perreault; R P Shannon; K Komamura; S F Vatner; J P Morgan
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

Review 6.  Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.

Authors:  Brian D Guth; Michael Engwall; Sandy Eldridge; C Michael Foley; Liang Guo; Gary Gintant; John Koerner; Stanley T Parish; Jennifer B Pierson; Alexandre J S Ribeiro; Tanja Zabka; Khuram W Chaudhary; Yasunari Kanda; Brian Berridge
Journal:  Front Pharmacol       Date:  2019-08-09       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.